These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

975 related articles for article (PubMed ID: 35680848)

  • 21. Applications of protein ubiquitylation and deubiquitylation in drug discovery.
    Chen Y; Xue H; Jin J
    J Biol Chem; 2024 May; 300(5):107264. PubMed ID: 38582446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PROTACs: Promising approach for anticancer therapy.
    Kaur SD; Bedi N; Kumar D; Kapoor DN
    Cancer Lett; 2023 Mar; 556():216065. PubMed ID: 36642326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
    Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
    Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PROTACs: An Emerging Therapeutic Modality in Precision Medicine.
    Nalawansha DA; Crews CM
    Cell Chem Biol; 2020 Aug; 27(8):998-1014. PubMed ID: 32795419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early evaluation of opportunities in oral delivery of PROTACs to overcome their molecular challenges.
    Yang W; Saboo S; Zhou L; Askin S; Bak A
    Drug Discov Today; 2024 Feb; 29(2):103865. PubMed ID: 38154757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PROTACs: past, present and future.
    Li K; Crews CM
    Chem Soc Rev; 2022 Jun; 51(12):5214-5236. PubMed ID: 35671157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent Advances in PROTACs for Drug Targeted Protein Research.
    Yao T; Xiao H; Wang H; Xu X
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PROTACS: A technology with a gold rush-like atmosphere.
    Wang YW; Lan L; Wang M; Zhang JY; Gao YH; Shi L; Sun LP
    Eur J Med Chem; 2023 Feb; 247():115037. PubMed ID: 36566716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.
    Chen Y; Tandon I; Heelan W; Wang Y; Tang W; Hu Q
    Chem Soc Rev; 2022 Jul; 51(13):5330-5350. PubMed ID: 35713468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in targeted protein degraders as potential therapeutic agents.
    Yang N; Kong B; Zhu Z; Huang F; Zhang L; Lu T; Chen Y; Zhang Y; Jiang Y
    Mol Divers; 2024 Feb; 28(1):309-333. PubMed ID: 36790583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
    An S; Fu L
    EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.
    Burslem GM; Crews CM
    Cell; 2020 Apr; 181(1):102-114. PubMed ID: 31955850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent Developments in Medicinal Chemistry and Therapeutic Potential of Anti-Cancer PROTACs-Based Molecules.
    Irshad Khan MZ; Nazli A; Pan YL; Chen JZ
    Curr Med Chem; 2023; 30(14):1576-1622. PubMed ID: 35927805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
    Zhu H; Wang J; Zhang Q; Pan X; Zhang J
    Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin-Proteasome system.
    Xie H; Zhang C
    Eur J Med Chem; 2024 Mar; 267():116168. PubMed ID: 38310686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.
    Pettersson M; Crews CM
    Drug Discov Today Technol; 2019 Apr; 31():15-27. PubMed ID: 31200855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PROTACs in Treatment of Cancer: A Review.
    Arora P; Singh M; Singh V; Bhatia S; Arora S
    Mini Rev Med Chem; 2021; 21(16):2347-2360. PubMed ID: 33634757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ligandability of E3 Ligases for Targeted Protein Degradation Applications.
    Belcher BP; Ward CC; Nomura DK
    Biochemistry; 2023 Feb; 62(3):588-600. PubMed ID: 34473924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The rise of covalent proteolysis targeting chimeras.
    Gabizon R; London N
    Curr Opin Chem Biol; 2021 Jun; 62():24-33. PubMed ID: 33549806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.